

**References for Articles Appearing in the Fall, 2011 Edition of  
The Maryland Family Doctor  
Theme: Selected Issues in Women's Health**

**Life After Breast Cancer** by Lauren A. Gordon, M.D. with Nancy Beth Barr, M.D. (p. 7)

1. Kantsiper, M; McDonald, E, et al. Transitioning to Breast Cancer survivorship: Perspectives of Patients, Cancer Specialists, and Primary Care Physicians. *JGIM*. 2009;24 (Suppl 2):459-66.
2. Khatcheressian, J. Wolff, A, et al. American Society of Clinical Oncology 2006 Update of the Breast cancer Follow-up and Management Guidelines in the Adjuvant Setting. *J Clin Oncology*. 2006;24:5091-5097.
3. Hayes, Daniel. Follow-up of Patients with Early Breast Cancer. *New Engl J Med*. 2007;356(24):2505-2513.
4. Snyder, C, Frick, K., et al. Comparing Care for Breast Cancer Survivorship to Non-Cancer Controls: A Five-Year Longitudinal Study. *JGIM*. 2009;24(4):469-74.
5. Centers for Disease Control and Prevention (CDC). [Cancer survivors—United States, 2007](#). *MMWR* 2011;60(9):269–272.

\*\*\*\*\*

**Provision of Early Medical Abortion** by Zowie S. Barnes, M.D. (p. 9)

- <sup>1</sup> Paul, Maureen E, et al; *Management of Unintended and Abnormal Pregnancy* Chapter 9 Medical abortion in early pregnancy 111-134; Wiley-Blackwell: 2009
- <sup>1</sup> Finer, Lawrence B, PhD and Wei, Junhow; “*Effect of Mifepristone on Abortion Access in the United States*”; *Obstetrics & Gynecology* Volume 114, Number 3, Pages 623-630, September 2009
- <sup>1</sup> Finer, Lawrence B, PhD and Wei, Junhow; “*Effect of Mifepristone on Abortion Access in the United States*”; *Obstetrics & Gynecology* 114(3): 623-630, September 2009
- <sup>1</sup> Jones, Rachel K, Zolna, Mia, Henshaw, Stanley K and Finer, Lawrence. “*Abortions in the United States: Incidence and Access to Services, 2005*”; *Perspectives on Sexual and Reproductive Health*, March 2008, 40(1):6-16
- <sup>1</sup> [www.guttmacher.org](http://www.guttmacher.org); Guttmacher Institute, In Brief;” *Facts on Induced Abortion In the United States*”; May 2011

\*\*\*\*\*

**Importance of Screening for Sexual Dysfunctions** by Adrienne A. Williams, Ph.D. (p. 11)

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. *JAMA: Journal of the American Medical Association*. 1999;281(6):537-544.
2. Zakhari R. Female sexual dysfunction: A primary care perspective. *J Am Acad Nurse Pract*. 2009;21(9):498-505.
3. Kingsberg SA. Taking a sexual history. *Obstetrics and Gynecology Clinics of North America*. 2006;33:535-347.

4. Murtagh J. Female sexual function, dysfunction, and pregnancy: Implications for practice. *J Midwifery Womens Health*. 2010;55(5):438-446.
5. Moreira ED, Brock G, Glasser DB, et al. Help-seeking behaviour for sexual problems: the Global Study of Sexual Attitudes and Behaviors. *Int J Clin Pract*. 2005;59(1):6-16. doi: 10.1111/j.1742-1241.2005.00382.x.
6. Bachmann GA, Leiblum SR, Grill J. Brief sexual inquiry in gynecologic practice. *Obstet Gynecol*. 1989;73(3 Pt 1):425-427.
7. Bullard DG, Caplan H, Derzko C. Sexual Problems. In: *Behavioral Medicine: A guide for clinical practice*. Third Edition ed. McGraw-Hill; US; 2008:303-321.
8. Abdolrasulnia M, Shewchuk RM, Roepke N, et al. Management of female sexual problems: Perceived barriers, practice patterns, and confidence among primary care physicians and gynecologists. *Journal of Sexual Medicine*. 2010;7(7):2499-2508.
9. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. Fourth Edition, Text Revision ed. Arlington, VA: American Psychiatric Association; 2000. Accessed 12/16/2009.

\*\*\*\*\*

### **Identification and Prevention of the Female Athlete Triad** by Valerie E. Cothran, M.D. (p. 13)

- Beals KA, Meyer NL. Female athlete triad update. *Clin Sports Med*. Jan 2007;26(1):69-89.
- Bonci CM, Bonci LJ, Granger LR, Johnson CL, Malina RM, Milne LW, et al. National athletic trainers' association position statement: preventing, detecting, and managing disordered eating in athletes. *J Athl Train*. Jan-Mar 2008;43(1):80-108
- Brunet M 2nd. Female athlete triad. *Clin Sports Med*. Jul 2005;24(3):623-36, ix
- Hoch AZ, Pajewski NM, et al. Prevalence of the female athlete triad in high school athletes and sedentary students. *Clin J Sport Med*. 2009 Sep;19(5):421-8
- Joy, E.A., Van Hala, S., and Cooper, L. Health-related concerns of the Female Athlete: A lifespan approach *American Family Physician* March 79(6): 489-49
- Lebrun CM. The female athlete triad: what's a doctor to do?. *Curr Sports Med Rep*. Dec 2007;6(6):397-404
- Loucks AB. Low energy availability in the marathon and other endurance sports . *Sports Med*. 2007;37(4-5):348-52
- Mendelsohn FA, Warren MP Anorexia, bulimia, and the female athlete triad: evaluation and management *Endocrinol Metab Clin North Am* 39(1):155-67 (2010)
- Nattiv A, Loucks AB, Manore MM, et al. American College of Sports Medicine position stand. The female athlete triad. *Med Sci Sports Exerc*. Oct 2007;39(10):1867-82
- Zach KN. Advances in management of the female athlete triad and eating disorders . *Clin Sport Med* 30:551 (2011)

\*\*\*\*\*

### **Treating Acne – With Special Considerations for Women** by Rayne A. Edmonds, M.D. (p. 16)

1. Aamir Haider, MD, PharmD; James C. Shaw, MD, FRCPC, Treatment of Acne Vulgaris, *JAMA*. 2004;292(6):726-735
2. **James C. Shaw MD** *Journal of the American Academy of Dermatology* Volume 43, Issue 3, September 2000, Pages 498-502  
Katharine O'Connell, MD, MPH; Carolyn Westhoff, MD, Pharmacology of Hormonal
3. Contraceptives and Acne, *Cutaneous Medicine for the Practitioner* 2008; 81: 10-14

4. Phoebe Rich, MD, Hormonal Contraceptives for Acne Management, *Cutaneous Medicine for the Practitioner* 2008; 81: 15-20
5. *Tobechi L. Ebede, MD, Weill-Cornell Medical Center, Emily L. Arch, MD, et al, [Hormonal Treatment, Literature Review Hormonal Treatment of Acne in Women](#)* , *The Journal of Clinical and Aesthetic Dermatology* 2009;2(12):16–22.
6. Collier C, Harper J, Cantrell W, et al. The prevalence of acne in adults 20 years and older. *J Am Acad Dermatol.* 2008;58:56–59.
7. Dreno B, Poli F. Epidemiology of acne. *Dermatology.* 2003;206:7–10.
8. James W. Acne. *N Engl J Med.* 2005;352;14:1463–1472.
9. Goulden V, Clark S, Cunliffe W. Post-adolescent acne: a review of clinical features. *Br J Dermatol.* 1997;136:66–70.
10. Thiboutot D, Gollnick H, Betolli V, et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group. *J Am Acad Dermatol.* 2009; 60:S1–S50.
11. Diane M. Thiboutot, MD, Overview of Acne and Its Treatment, *Cutaneous Medicine for the Practitioner* 2008; 81: 5-9
12. Webster GF. Acne vulgaris. *BMJ.* 2002;325:475-479.
13. Gollnick H, Cunliffe W, Berson D, et al, and the Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. *J Am Acad Dermatol.* 2003;49(suppl 1):S1-S37.
14. Thorneycroft IH. Evolution of progestins. Focus on the novel progestin drospirenone. *J Reprod Med.* 2002;47:975–980.
15. Maloney M, Arbit D, Flack M, et al. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. *Clin J Women’s Health.* 2001;1:123–131.
16. Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. *Climacteric.* 2008;11:355–363
17. Feldman S, Carreccia R, et al. Diagnosis and Treatment of Acne. *American Family Physician.* 2004; 69: 2123-30
18. Cunliffe WJ, Holland KT, Bojar R, Levy SF, A randomized , double blind comparison of clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the treatment of acne vulgaris. *Clin Ther* 2002;24:1117-33
19. Frangos JE, Alavian CN, Kimball AB. Acne and oral contraceptives: update on women’s health screening guidelines. *J Am Acad Dermatol.* 2008;58:781–786.
20. Van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. *Cutis.* 2002;69(suppl 4):2–15.
21. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. *Cutis.* 2004;74:123–130.
22. Landau M MD , Chemical peels [Clinics in Dermatology](#) 2008; [26;2](#): 200-208
23. Zakopoulou MD, G Kontochristopoulos MD, Superficial Chemical Peels, *Journal of Cosmetic Dermatology* 2006; 5;3: 246–253
24. Kempniak SJ MD, PhD, Uebelhoer N DO Acne Therapy [Seminars in Cutaneous Medicine and Surgery.](#) 2008; 27;3: 212-220
25. Diane M. Thiboutot, MD, Overview of Acne and Its Treatment. *Cutis.* 2008;81(suppl 1):3-7.